Eli Lilly’s ($LLY@US) weight loss drug, Tirzepatide, helped patients with Type 2 diabetes and overweight patients lose up to 34 pounds on average, or 16% of their body weight, in a clinical trial. The drug, approved by the FDA for Type 2 diabetes, but not for weight loss, is expected to receive regulatory action later this year. Critics warn of the potential dangers of increased use of such drugs in perpetuating diet culture, and some patients report weight rebound after discontinuing the medication. Tirzepatide mimics two gut hormones that signal fullness, suppressing appetite, and is set to be tested against rival drug Wegovy in a new clinical trial.

Leave a Reply

Your email address will not be published. Required fields are marked *